Drug firm Orchid Chemicals & Pharmaceuticals has informed that the company has received final nod from US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Zaleplon Capsules.      The drug is used for the treatment of insomnia.

Orchid Chemicals stated in a release that it will sell the Zaleplon Capsules in the strengths of 5 mg and 10 mg.

The company statement said that with this approval, the total ANDA approval count of Orchid has gone up to 37, while the total ANDA filings stand at 58.

It should be noted that earlier this week (September 16), the Chennai-based pharma major has also received regulator's final nod for its Piperacillin and Tazobactam injection.